# Dimitrios Farmakis

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1611849/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 153 papers | 14,470 citations | 61687 45 h-index | 25983 112 g-index |
| 155 all docs | 155 docs citations | 155 times ranked | 12384 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Journal of Heart Failure, 2022, 24, 4-131. | 2.9 | 820 |
| 2 | Anticoagulation for atrial fibrillation in active cancer (Review). Oncology Letters, 2022, 23, 124. | 0.8 | 6 |
| 3 | Atrial disease and heart failure: the common soil hypothesis proposed by the Heart Failure Association of the European Society of Cardiology. European Heart Journal, 2022, 43, 863-867. | 1.0 | 14 |
| 4 | GuÃa ESC 2021 sobre el diagnÃ³stico y tratamiento de la insuficiencia cardiaca aguda y crÃ³nica. Revista Espanola De Cardiologia, 2022, 75, 523.e1-523.e114. | 0.6 | 40 |
| 5 | Biomarkers for the prediction of heart failure and cardiovascular events in patients with type 2 diabetes: a position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2022, 24, 1162-1170. | 2.9 | 13 |
| 6 | Interatrial Block Predicts Lifeâ€Threatening Arrhythmias in Dilated Cardiomyopathy. Journal of the American Heart Association, 2022, 11, . | 1.6 | 4 |
| 7 | Right ventricular involvement in cancer therapyâ€“related cardiotoxicity: the emerging role of strain echocardiography. Heart Failure Reviews, 2021, 26, 1189-1193. | 1.7 | 20 |
| 8 | Arrhythmias in cancer: rhythm is gonna get you!. European Journal of Heart Failure, 2021, 23, 154-156. | 2.9 | 8 |
| 9 | Extracorporeal life support at the emergency department: new insights into the management of acute cardiac care patients. Hellenic Journal of Cardiology, 2021, 62, 46-47. | 0.4 | 0 |
| 10 | A critical appraisal of the pharmacological management of stable angina. Hellenic Journal of Cardiology, 2021, 62, 135-138. | 0.4 | 1 |
| 11 | Patient profiling in heart failure for tailoring medical therapy. A consensus document of the ‹scp›Heart Failure Association of the European Society of Cardiology‹/scp›. European Journal of Heart Failure, 2021, 23, 872-881. | 2.9 | 160 |
| 12 | Association between upâ€titration of medical therapy and total hospitalizations and mortality in patients with recent worsening heart failure across the ejection fraction spectrum. European Journal of Heart Failure, 2021, 23, 1170-1181. | 2.9 | 11 |
| 13 | 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 2021, 42, 3599-3726. | 1.0 | 5,558 |
| 14 | Oral sucrosomial iron improves exercise capacity and quality of life in heart failure with reduced ejection fraction and iron deficiency: a nonâ€randomized, openâ€label, proofâ€ofâ€concept study. European Journal of Heart Failure, 2021, 23, 593-597. | 2.9 | 21 |
| 15 | Anticoagulation for atrial fibrillation in active cancer: what the cardiologists think. European Journal of Preventive Cardiology, 2021, 28, 608-610. | 0.8 | 16 |
| 16 | Levosimendan in Europe and China: An Appraisal of Evidence and Context. European Cardiology Review, 2021, 16, e42. | 0.7 | 1 |
| 17 | Impact of SGLT2 inhibitors on major clinical events and safety outcomes in heart failure patients: a meta-analysis of randomized clinical trials. Journal of Geriatric Cardiology, 2021, 18, 783-795. | 0.2 | 7 |
| 18 | Quality of Life is Related to Haemodynamics in Precapillary Pulmonary Hypertension. Heart Lung and Circulation, 2020, 29, 142-148. | 0.2 | 11 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Levosimendan prevents doxorubicin-induced cardiotoxicity in time- and dose-dependent manner: implications for inotropy. Cardiovascular Research, 2020, 116, 576-591. | 1.8 | 32 |
| 20 | Distribution, infrastructure, and expertise of heart failure and cardioâ€oncology clinics in a developing network: temporal evolution and challenges during the coronavirus disease 2019 pandemic. ESC Heart Failure, 2020, 7, 3408-3413. | 1.4 | 6 |
| 21 | Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the <scp>Cardioâ€Oncology Study Group</scp> of the <scp>Heart Failure Association</scp> and the <scp>Cardioâ€Oncology Council of the European Society of Cardiology</scp>. European Journal of Heart Failure, 2020, 22, 1966-1983. | 2.9 | 184 |
| 22 | Differential effects of inotropes and inodilators on renal function in acute cardiac care. European Heart Journal Supplements, 2020, 22, D12-D19. | 0.0 | 10 |
| 23 | Is cardioâ€oncology a rapidly growing field of precision medicine?. European Journal of Heart Failure, 2020, 22, 2310-2313. | 2.9 | 6 |
| 24 | Focused echocardiography in cardioâ€oncology. Echocardiography, 2020, 37, 1149-1158. | 0.3 | 11 |
| 25 | Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the <scp>Translational Research Committee</scp> of the <scp>Heart Failure Association</scp> (<scp>HFA</scp>) of the <scp>European Society of Cardiology</scp> (<scp>ESC</scp>). European Journal of Heart Failure, 2020, 22, 2272-2289. | 2.9 | 92 |
| 26 | Assessing frailty in heart failure. European Journal of Heart Failure, 2020, 22, 2134-2137. | 2.9 | 6 |
| 27 | Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the <scp>C</scp>ardioâ€<scp>O</scp>ncology <scp>S</scp>tudy <scp>G</scp>roup of the <scp>H</scp>eart <scp>F</scp>ailure <scp>A</scp>ssociation of the <scp>E</scp>uropean <scp>S</scp>ociety of <scp>C</scp>ardiology in collaboration with the <scp>I</scp>nternational <scp>C</scp>ardioâ€<scp>O</scp>ncology <scp>S</scp>ociety. European Journal of Heart Failure, 2020, | 2.9 | 364 |
| 28 | The management of atrial fibrillation in heart failure: an expert panel consensus. Heart Failure Reviews, 2020, 26, 1345-1358. | 1.7 | 15 |
| 29 | Sodiumâ€“glucose coâ€transporter 2 inhibitors: â€˜a tale of two sistersâ€™, diabetes and heart failure. European Journal of Heart Failure, 2020, 22, 1259-1262. | 2.9 | 2 |
| 30 | The changing epidemiology of the ageing thalassaemia populations: A position statement of the Thalassaemia International Federation. European Journal of Haematology, 2020, 105, 16-23. | 1.1 | 35 |
| 31 | Cancer treatment and atrial fibrillation: use of pharmacovigilance databases to detect cardiotoxicity. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 7, 321-323. | 1.4 | 9 |
| 32 | Levosimendan Efficacy and Safety: 20 Years of SIMDAX in Clinical Use. Journal of Cardiovascular Pharmacology, 2020, 76, 4-22. | 0.8 | 49 |
| 33 | COVIDâ€19 and thalassaemia: A position statement of the Thalassaemia International Federation. European Journal of Haematology, 2020, 105, 378-386. | 1.1 | 31 |
| 34 | Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the <scp>H</scp>eart <scp>F</scp>ailure <scp>A</scp>ssociation (<scp>HFA</scp>), the <scp>E</scp>uropean <scp>A</scp>ssociation of <scp>C</scp>ardiovascular <scp>I</scp>maging (<scp>EACVI</scp>) and the <scp>Cardioâ€Oncology C</scp>ouncil of the <scp>E</scp>uropean <scp>S</scp>ociety of <scp>C</scp>ardiology (<scp>ESC</scp>). European Journal of Heart Failure, 2020, 22, 1504-1524. | 2.9 | 234 |
| 35 | How to develop a national heart failure clinics network: a consensus document of the Hellenic Heart Failure Association. ESC Heart Failure, 2020, 7, 15-25. | 1.4 | 10 |
| 36 | High-sensitivity cardiac troponin assays for cardiovascular risk stratification in the general population. European Heart Journal, 2020, 41, 4050-4056. | 1.0 | 83 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Cardioâ€oncology services during the <scp>COVID</scp>â€19 pandemic: practical considerations and challenges. European Journal of Heart Failure, 2020, 22, 929-932. | 2.9 | 4 |
| 38 | Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry. European Heart Journal, 2020, 41, 1720-1729. | 1.0 | 154 |
| 39 | Levosimendan Efficacy and Safety: 20 years of SIMDAX in Clinical Use. Cardiac Failure Review, 2020, 6, e19. | 1.2 | 37 |
| 40 | Telephone based survey in adults with congenital heart disease during COVID-19 pandemic. Cardiology Journal, 2020, 27, 636-638. | 0.5 | 8 |
| 41 | Cardiogenic shock in cancer. Heart Failure Reviews, 2019, 24, 997-1004. | 1.7 | 15 |
| 42 | A look back: the quest for thrombosis in heart failure continues after COMMANDER HF. Cardiovascular Research, 2019, 115, e140-e142. | 1.8 | 4 |
| 43 | Short-Term Therapies for Treatment of Acute and Advanced Heart Failureâ€"Why so Few Drugs Available in Clinical Use, Why Even Fewer in the Pipeline?. Journal of Clinical Medicine, 2019, 8, 1834. | 1.0 | 14 |
| 44 | A pragmatic approach to the use of inotropes for the management of acute and advanced heart failure: An expert panel consensus. International Journal of Cardiology, 2019, 297, 83-90. | 0.8 | 42 |
| 45 | Cardiovascular complications of metastatic colorectal cancer treatment. Journal of Gastrointestinal Oncology, 2019, 10, 797-806. | 0.6 | 13 |
| 46 | Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2019, 21, 553-576. | 2.9 | 224 |
| 47 | Longitudinal changes of right ventricular deformation mechanics during trastuzumab therapy in breast cancer patients. European Journal of Heart Failure, 2019, 21, 529-535. | 2.9 | 56 |
| 48 | Recent advances in cardioâ€oncology: a report from the â€˜Heart Failure Association 2019 and World Congress on Acute Heart Failure 2019â€™. ESC Heart Failure, 2019, 6, 1140-1148. | 1.4 | 34 |
| 49 | Practical Recommendations for the Diagnosis and Medical Management of Stable Angina. Journal of Cardiovascular Pharmacology, 2019, 74, 308-314. | 0.8 | 4 |
| 50 | Alternative Modes of Exercise Training in Heart Failure With Preserved Ejection Fraction: Is It Time to Give Them Serious Consideration?. Revista Espanola De Cardiologia (English Ed ), 2019, 72, 279-281. | 0.4 | 0 |
| 51 | Modelos alternativos de ejercicios de entrenamiento en la insuficiencia cardiaca con funciÃ³n conservada: Â¿es el momento para su implementaciÃ³n?. Revista Espanola De Cardiologia, 2019, 72, 279-281. | 0.6 | 0 |
| 52 | Cancer diagnosis in patients with heart failure: epidemiology, clinical implications and gaps in knowledge. European Journal of Heart Failure, 2018, 20, 879-887. | 2.9 | 138 |
| 53 | Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2018, 20, 853-872. | 2.9 | 434 |
| 54 | Anthracyclineâ€induced cardiomyopathy: secrets and lies. European Journal of Heart Failure, 2018, 20, 907-909. | 2.9 | 24 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Renin inhibition in heart failure and diabetes: the real story. European Journal of Heart Failure, 2018, 20, 149-151. | 2.9 | 7 |
| 56 | Effects of functional electrical stimulation of lower limb muscles on circulating endothelial progenitor cells, CD34+ cells and vascular endothelial growth factorâ€A in heart failure with reduced ejection fraction. European Journal of Heart Failure, 2018, 20, 1162-1163. | 2.9 | 2 |
| 57 | Hypothalamic dysfunction in heart failure: pathogenetic mechanisms and therapeutic implications. Heart Failure Reviews, 2018, 23, 55-61. | 1.7 | 11 |
| 58 | Association of mineralocorticoid receptor antagonist use and in-hospital outcomes in patients with acute heart failure. Clinical Research in Cardiology, 2018, 107, 76-86. | 1.5 | 15 |
| 59 | Ups and downs in heart failure: the case of proteomics. European Journal of Heart Failure, 2018, 20, 63-66. | 2.9 | 6 |
| 60 | Modernâ€day cardioâ€oncology: a report from the â€˜Heart Failure and World Congress on Acute Heart Failure 2018â€™. ESC Heart Failure, 2018, 5, 1083-1091. | 1.4 | 23 |
| 61 | Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Associationâ€“European Society of Cardiology. European Heart Journal, 2018, 39, 4243-4254. | 1.0 | 171 |
| 62 | Anti-Thrombotic Therapy after Trans-Catheter Aortic Valve Implantation: Time for Refinement. Cardiology, 2018, 141, 66-68. | 0.6 | 1 |
| 63 | Heart Disease in Patients with Haemoglobinopathies. Thalassemia Reports, 2018, 8, 7480. | 0.1 | 0 |
| 64 | How to build a cardioâ€oncology service?. European Journal of Heart Failure, 2018, 20, 1732-1734. | 2.9 | 27 |
| 65 | Direct Oral Anticoagulants in Nonvalvular Atrial Fibrillation: Practical Considerations on the Choice of Agent and Dosing. Cardiology, 2018, 140, 126-132. | 0.6 | 19 |
| 66 | Serelaxin in acute heart failure patients with and without atrial fibrillation: a secondary analysis of the RELAX-AHF trial. Clinical Research in Cardiology, 2017, 106, 444-456. | 1.5 | 8 |
| 67 | Effect of functional electrical stimulation on cardiovascular outcomes in patients with chronic heart failure. European Journal of Preventive Cardiology, 2017, 24, 833-839. | 0.8 | 11 |
| 68 | How to Use Beta-Blockers in Heart FailureÂWith Reduced Ejection Fraction and Atrial Fibrillation â^—. Journal of the American College of Cardiology, 2017, 69, 2897-2900. | 1.2 | 10 |
| 69 | Acute heart failure with mid-range left ventricular ejection fraction: clinical profile, in-hospital management, and short-term outcome. Clinical Research in Cardiology, 2017, 106, 359-368. | 1.5 | 57 |
| 70 | Heart failure in haemoglobinopathies: pathophysiology, clinical phenotypes, andÂmanagement. European Journal of Heart Failure, 2017, 19, 479-489. | 2.9 | 31 |
| 71 | Protocol update and preliminary results of EACVI/HFA Cardiac Oncology Toxicity (COT) Registry of the European Society of Cardiology. ESC Heart Failure, 2017, 4, 312-318. | 1.4 | 22 |
| 72 | Percutaneous coronary intervention reduces mortality in myocardial infarction patients with comorbidities: Implications for elderly patients with diabetes or kidney disease. International Journal of Cardiology, 2017, 249, 83-89. | 0.8 | 21 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. European Journal of Heart Failure, 2017, 19, 9-42. | 2.9 | 920 |
| 74 | Heart failure registries: how far can we go?. European Journal of Heart Failure, 2016, 18, 626-628. | 2.9 | 8 |
| 75 | Levosimendan beyond inotropy and acute heart failure: Evidence of pleiotropic effects on the heart and other organs: An expert panel position paper. International Journal of Cardiology, 2016, 222, 303-312. | 0.8 | 103 |
| 76 | Practical considerations on the introduction of sacubitril/valsartan in clinical practice: Current evidence and early experience. International Journal of Cardiology, 2016, 223, 781-784. | 0.8 | 9 |
| 77 | Structured discharge instructions for hospitalized heart failure patients to improve guideline implementation and patient outcomes. International Journal of Cardiology, 2016, 220, 143-145. | 0.8 | 3 |
| 78 | Natriuretic peptides revisited. Journal of Cardiovascular Medicine, 2016, 17, 840-842. | 0.6 | 2 |
| 79 | Body mass index in acute heart failure: association with clinical profile, therapeutic management and inâ€hospital outcome. European Journal of Heart Failure, 2016, 18, 298-305. | 2.9 | 25 |
| 80 | Urine proteome analysis in heart failure with reduced ejection fraction complicated by chronic kidney disease: feasibility, and clinical and pathogenetic correlates. European Journal of Heart Failure, 2016, 18, 822-829. | 2.9 | 28 |
| 81 | Diet and Exercise for Obese Patients With Heart Failure. JAMA - Journal of the American Medical Association, 2016, 315, 2618. | 3.8 | 0 |
| 82 | The medical and socioeconomic burden of heart failure: A comparative delineation with cancer. International Journal of Cardiology, 2016, 203, 279-281. | 0.8 | 64 |
| 83 | Functional electrical stimulation of lower limb muscles as an alternative mode of exercise training in chronic heart failure: practical considerations and proposed algorithm. European Journal of Heart Failure, 2015, 17, 1228-1230. | 2.9 | 19 |
| 84 | Overcoming the ethnic differences in patients hospitalized for heart failure: is there a need for international harmonization of clinical practice guidelines?. European Journal of Heart Failure, 2015, 17, 755-757. | 2.9 | 5 |
| 85 | Transient carotid ischemia as a remote conditioning stimulus for myocardial protection in anesthetized rabbits: Insights into intracellular signaling. International Journal of Cardiology, 2015, 184, 140-151. | 0.8 | 14 |
| 86 | Prognostic value of in-hospital change in cystatin C in patients with acutely decompensated heart failure and renal dysfunction. International Journal of Cardiology, 2015, 182, 74-76. | 0.8 | 15 |
| 87 | Acute Heart Failure: Epidemiology, Risk Factors, and Prevention. Revista Espanola De Cardiologia (English Ed ), 2015, 68, 245-248. | 0.4 | 64 |
| 88 | Ligands involved in conditioning may enhance the protection afforded by remote ischemia and reperfusion. International Journal of Cardiology, 2015, 190, 273-274. | 0.8 | 2 |
| 89 | Drug therapy for patients with systolic heart failure after the PARADIGM-HF trial: in need of a new paradigm of LCZ696 implementation in clinical practice. BMC Medicine, 2015, 13, 35. | 2.3 | 23 |
| 90 | Myocardial deformation imaging unmasks subtle left ventricular systolic dysfunction in asymptomatic and treatment-naÃ¯ve HIV patients. Clinical Research in Cardiology, 2015, 104, 975-981. | 1.5 | 14 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Efficacy and safety of functional electrical stimulation of lower limb muscles in elderly patients with chronic heart failure: A pilot study. European Journal of Preventive Cardiology, 2015, 22, 831-836. | 0.8 | 19 |
| 92 | In-hospital management of acute heart failure: Practical recommendations and future perspectives. International Journal of Cardiology, 2015, 201, 231-236. | 0.8 | 31 |
| 93 | Determinants of the direct cost of heart failure hospitalization in a public tertiary hospital. International Journal of Cardiology, 2015, 180, 46-49. | 0.8 | 35 |
| 94 | Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trial. European Heart Journal, 2014, 35, 1041-1050. | 1.0 | 90 |
| 95 | Insights Into Onco-Cardiology. Journal of the American College of Cardiology, 2014, 63, 945-953. | 1.2 | 295 |
| 96 | Oleuropein prevents doxorubicin-induced cardiomyopathy interfering with signaling molecules and cardiomyocyte metabolism. Journal of Molecular and Cellular Cardiology, 2014, 69, 4-16. | 0.9 | 98 |
| 97 | Renal dysfunction and heart failure: things are seldom what they seem. European Heart Journal, 2014, 35, 416-418. | 1.0 | 58 |
| 98 | International differences in acute coronary syndrome patientsâ€™ baseline characteristics, clinical management and outcomes in Western Europe: the EURHOBOP study. Heart, 2014, 100, 1201-1207. | 1.2 | 56 |
| 99 | Selenium contributes to myocardial injury and cardiac remodeling in heart failure. International Journal of Cardiology, 2014, 176, 272-273. | 0.8 | 18 |
| 100 | Cardioâ€“renoâ€“hepatic interactions in acute heart failure: The role of Î³-glutamyl transferase. International Journal of Cardiology, 2014, 173, 556-557. | 0.8 | 7 |
| 101 | Novel Biomarkers in Acute Coronary Syndromes. Journal of the American College of Cardiology, 2014, 63, 1654-1656. | 1.2 | 7 |
| 102 | Differences in clinical characteristics, management and short-term outcome between acute heart failure patients chronic obstructive pulmonary disease and those without this co-morbidity. Clinical Research in Cardiology, 2014, 103, 733-741. | 1.5 | 32 |
| 103 | Temporal trends in epidemiology, clinical presentation and management of acute heart failure: results from the Greek cohorts of the Acute Heart Failure Global Registry of Standard Treatment and the European Society of Cardiology-Heart Failure pilot survey. European Heart Journal: Acute Cardiovascular Care, 2014, , 204887261452701. | 0.4 | 20 |
| 104 | Anticoagulant therapy is prescribed less often in paroxysmal atrial fibrillation regardless of thromboembolic risk: Results from the Registry of Atrial Fibrillation To Investigate New Guidelines (RAFTING). International Journal of Cardiology, 2014, 175, 569-570. | 0.8 | 3 |
| 105 | Functional electrical stimulation of peripheral muscles improves endothelial function and clinical and emotional status in heart failure patients with preserved left ventricular ejection fraction. American Heart Journal, 2013, 166, 760-767. | 1.2 | 45 |
| 106 | Clinical and neurohormonal correlates and prognostic value of serum prolactin levels in patients with chronic heart failure. European Journal of Heart Failure, 2013, 15, 1122-1130. | 2.9 | 23 |
| 107 | Heart Failure 2013. Cardiology Research and Practice, 2013, 2013, 1-2. | 0.5 | 2 |
| 108 | Intravenous ferric carboxymaltose in ironâ€deficient chronic heart failure patients with and without anaemia: a subanalysis of the FAIRâ€HF trial. European Journal of Heart Failure, 2013, 15, 1267-1276. | 2.9 | 130 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Clinical profile and therapeutic management of patients with atrial fibrillation in Greece: results from the Registry of Atrial Fibrillation to Investigate New Guidelines (RAFTING). Hellenic Journal of Cardiology, 2013, 54, 368-75. | 0.4 | 4 |
| 110 | Echocardiographic Evaluation of Pulmonary Artery Pressure in Patients With Heart Failure. Journal of the American College of Cardiology, 2012, 60, 83. | 1.2 | 1 |
| 111 | High-Sensitivity Troponin Assays. Journal of the American College of Cardiology, 2012, 60, 166. | 1.2 | 8 |
| 112 | Clinical Characteristics and Predictors of In-Hospital Mortality in Acute Heart Failure With Preserved Left Ventricular Ejection Fraction. American Journal of Cardiology, 2011, 107, 79-84. | 0.7 | 38 |
| 113 | Pulmonary Hypertension Associated With Hemoglobinopathies. Circulation, 2011, 123, 1227-1232. | 1.6 | 85 |
| 114 | Iron Overload Cardiomyopathy in Clinical Practice. Circulation, 2011, 124, 2253-2263. | 1.6 | 240 |
| 115 | Î²-Thalassemia Cardiomyopathy. Circulation: Heart Failure, 2010, 3, 451-458. | 1.6 | 171 |
| 116 | Plasma B-type natriuretic peptide reduction predicts long-term response to levosimendan therapy in acutely decompensated chronic heart failure. International Journal of Cardiology, 2010, 139, 75-79. | 0.8 | 23 |
| 117 | Selfâ€assessment of health status is associated with inflammatory activation and predicts longâ€term outcomes in chronic heart failure. European Journal of Heart Failure, 2009, 11, 163-169. | 2.9 | 51 |
| 118 | The prognostic role of echocardiographic indices in chronic heart failure: right ventricle revisited. European Journal of Heart Failure, 2009, 11, 1220-1220. | 2.9 | 2 |
| 119 | Plasma B-type natriuretic peptide and anti-inflammatory cytokine interleukin-10 levels predict adverse clinical outcome in chronic heart failure patients with depressive symptoms: a 1-year follow-up study. European Journal of Heart Failure, 2009, 11, 967-972. | 2.9 | 33 |
| 120 | Hyponatremia in heart failure. Heart Failure Reviews, 2009, 14, 59-63. | 1.7 | 54 |
| 121 | Cardiac involvement in sickle Î²-thalassemia. Annals of Hematology, 2009, 88, 557-564. | 0.8 | 17 |
| 122 | Effects of levosimendan on flow-mediated vasodilation and soluble adhesion molecules in patients with advanced chronic heart failure. Atherosclerosis, 2008, 197, 278-282. | 0.4 | 70 |
| 123 | Treadmill exercise test with dual isotope scintigraphy documents the second window of preconditioning in humans. Atherosclerosis, 2008, 198, 122-128. | 0.4 | 8 |
| 124 | Anticoagulants, Antiplatelets, and Statins in Heart Failure. Cardiology Clinics, 2008, 26, 49-58. | 0.9 | 12 |
| 125 | Effects of functional electrical stimulation on quality of life and emotional stress in patients with chronic heart failure secondary to ischaemic or idiopathic dilated cardiomyopathy: A randomised, placeboâ€controlled trial. European Journal of Heart Failure, 2008, 10, 709-713. | 2.9 | 38 |
| 126 | Heart disease in thalassemia intermedia: a review of the underlying pathophysiology. Haematologica, 2007, 92, 658-665. | 1.7 | 96 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | Plasma B-type natriuretic peptide concentration in Î²-thalassaemia patients. European Journal of Heart Failure, 2007, 9, 537-541. | 2.9 | 12 |
| 128 | Endothelial function and arterial stiffness in sickle-thalassemia patients. Atherosclerosis, 2007, 191, 427-432. | 0.4 | 61 |
| 129 | Levosimendan for the Treatment of Acute Heart Failure Syndromes: Time to Identify Subpopulations of Responding Patients. American Journal of Cardiology, 2007, 99, 146-147. | 0.7 | 14 |
| 130 | Intensive chelation therapy in Î²-thalassemia and possible adverse cardiac effects of desferrioxamine. International Journal of Hematology, 2007, 86, 212-215. | 0.7 | 20 |
| 131 | Classical inotropes and new cardiac enhancers. Heart Failure Reviews, 2007, 12, 149-156. | 1.7 | 79 |
| 132 | Functional electrical stimulation improves endothelial function and reduces peripheral immune responses in patients with chronic heart failure. European Journal of Cardiovascular Prevention and Rehabilitation, 2006, 13, 592-597. | 3.1 | 70 |
| 133 | Aortic Valve Replacement in a Patient With Thalassemia Intermedia. Annals of Thoracic Surgery, 2006, 81, 737-739. | 0.7 | 14 |
| 134 | Effects of Levosimendan Versus Dobutamine on Inflammatory and Apoptotic Pathways in Acutely Decompensated Chronic Heart Failure. American Journal of Cardiology, 2006, 98, 102-106. | 0.7 | 117 |
| 135 | Effects of Levosimendan on Right Ventricular Function in Patients With Advanced Heart Failure. American Journal of Cardiology, 2006, 98, 1489-1492. | 0.7 | 103 |
| 136 | Effects of Levosimendan on Markers of Left Ventricular Diastolic Function and Neurohormonal Activation in Patients With Advanced Heart Failure. American Journal of Cardiology, 2005, 96, 423-426. | 0.7 | 94 |
| 137 | Myelodysplastic syndrome associated with multiple autoimmune disorders. Clinical Rheumatology, 2005, 24, 428-430. | 1.0 | 7 |
| 138 | Levosimendan for the treatment of acute heart failure syndromes. Expert Opinion on Pharmacotherapy, 2005, 6, 2741-2751. | 0.9 | 36 |
| 139 | Thalassemia Heart Disease. Chest, 2005, 127, 1523-1530. | 0.4 | 192 |
| 140 | Visual loss associated with angioid streaks in sickle thalassemia. Haematologica, 2005, 90, ECR02. | 1.7 | 2 |
| 141 | Comments on the European guidelines on cardiovascular disease prevention. European Heart Journal, 2004, 25, 619. | 1.0 | 2 |
| 142 | Rupture of chordae tendineae in patients with Î²-thalassemia. European Journal of Haematology, 2004, 72, 296-298. | 1.1 | 7 |
| 143 | Cardiac status in well-treated patients with thalassemia major. European Journal of Haematology, 2004, 73, 359-366. | 1.1 | 150 |
| 144 | Aneurysmatic dilatation of ascending aorta in a patient with ?-thalassemia and a pseudoxanthoma elasticum-like syndrome. Annals of Hematology, 2004, 83, 596-9. | 0.8 | 21 |

| # | Article | IF | Citations |
|---|---|---|---|
| 145 | Unstable angina associated with coronary arterial calcification in a thalassemia intermedia patient with a pseudoxanthoma elasticumâ€like syndrome. European Journal of Haematology, 2003, 70, 64-66. | 1.1 | 16 |
| 146 | Unstable angina associated with coronary arterial calcification in a thalassemia intermedia patient with a pseudoxanthoma elasticum-like syndrome. , 2003, 70, 64. | | 5 |
| 147 | Pathogenetic aspects of immune deficiency associated with beta-thalassemia. Medical Science Monitor, 2003, 9, RA19-22. | 0.5 | 57 |
| 148 | Unstable angina associated with coronary arterial calcification in a thalassemia intermedia patient with a pseudoxanthoma elasticum-like syndrome. European Journal of Haematology, 2003, 70, 64-6. | 1.1 | 5 |
| 149 | Elastic tissue abnormalities resembling pseudoxanthoma elasticum in Î² thalassemia and the sickling syndromes. Blood, 2002, 99, 30-35. | 0.6 | 136 |
| 150 | Exercise-induced myocardial perfusion abnormalities in sickle Î²-thalassemia: Tc-99m tetrofosmin gated SPECT imaging study. American Journal of Medicine, 2001, 111, 355-360. | 0.6 | 18 |
| 151 | Cardiac involvement in thalassemia intermedia: a multicenter study. Blood, 2001, 97, 3411-3416. | 0.6 | 254 |
| 152 | Doppler-Determined Peak Systolic Tricuspid Pressure Gradient in Persons with Normal Pulmonary Function and Tricuspid Regurgitation. Journal of the American Society of Echocardiography, 2000, 13, 645-649. | 1.2 | 41 |
| 153 | Pseudoxanthoma Elasticum Lesions and Cardiac Complications as Contributing Factors for Strokes in Î²-Thalassemia Patients. Stroke, 1997, 28, 2421-2424. | 1.0 | 46 |